Package 51662-1442-1

Brand: verapamil hci

Generic: verapamil hci
NDC Package

Package Facts

Identity

Package NDC 51662-1442-1
Digits Only 5166214421
Product NDC 51662-1442
Product ID 51662-1442_12506f53-54b9-53d1-e063-6294a90addc5
Description

2 mL in 1 VIAL (51662-1442-1)

Marketing

Marketing Status
Marketed Since 2019-12-22
Brand verapamil hci
Generic verapamil hci
Sample Package No

Linked Drug Pages (1)

VERAPAMIL HCI ndc-match (0.95)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVENOUS"], "spl_id": "12506f53-54b9-53d1-e063-6294a90addc5", "openfda": {"unii": ["V3888OEY5R"], "rxcui": ["1665057"], "spl_set_id": ["9a4f12ec-fe1c-a1b9-e053-2a95a90ac8e4"], "manufacturer_name": ["HF Acquisition Co LLC, DBA HealthFirst"]}, "finished": true, "packaging": [{"sample": false, "description": "2 mL in 1 VIAL (51662-1442-1)", "package_ndc": "51662-1442-1", "marketing_start_date": "20191222"}], "brand_name": "VERAPAMIL HCI", "product_id": "51662-1442_12506f53-54b9-53d1-e063-6294a90addc5", "dosage_form": "INJECTION", "pharm_class": ["Calcium Channel Antagonists [MoA]", "Calcium Channel Blocker [EPC]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "51662-1442", "generic_name": "VERAPAMIL HCI", "labeler_name": "HF Acquisition Co LLC, DBA HealthFirst", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VERAPAMIL HCI", "active_ingredients": [{"name": "VERAPAMIL HYDROCHLORIDE", "strength": "2.5 mg/mL"}], "application_number": "NDA018925", "marketing_category": "NDA", "marketing_start_date": "20191222", "listing_expiration_date": "20261231"}